Yijia Group CORP 10-Q quarterly reports

VitaNova Life Sciences Corp. reported a net loss for Q3 and the nine months ended January 31, 2026, despite significant revenue growth driven by its dietary supplement segment, primarily due to increased general and administrative expenses and cost of revenue.

Yijia Group Corp. reported a significant increase in revenue and gross profit for the three and six months ended October 31, 2025, driven by its dietary supplement segment, despite identifying material weaknesses in internal controls.

Yijia Group Corp. reported a net loss of $46,301 for the quarter ended July 31, 2025, a slight improvement from the prior year, despite a 4% decrease in total revenue.

Yijia Group Corp. reports a substantial revenue increase in Q3 2025, primarily driven by the commencement of its healthcare products segment.

Yijia Group Corp. reports its first revenue from healthcare products and consulting services in its 10-Q filing for the period ended October 31, 2024, while also disclosing material weaknesses in internal controls.

Yijia Group Corp. reports its first revenue of $108,477 in the first quarter of 2025, primarily from healthcare product sales, but still experiences a net loss of $55,211.

Yijia Group Corp. saw a revenue increase in the third quarter of 2024 compared to 2023, but a decrease over the nine month period, while also completing a private offering that raised $957,051.